In this review, we describe the current laboratory approach to quantitative chimerism testing based on short tandem repeats (STRs), focusing on a longitudinal analysis. The latter is based on relative changes appearing in the course of sequential samples, and as such exploits the ultimate potential of this intrinsically semiquantitative platform. Such an analysis is more informative than single static values, less likely to be confused with platform artifacts, and is individualized to the particular patient. It is particularly useful with non-myeloablative conditioning, where mixed chimerism is common. Importantly, longitudinal monitoring is a routinely feasible laboratory option because multiplex STR-polymerase chain reaction kits are available commercially, and modern software can be used to perform computation, reliability testing and longitudinal tracking in a rapid, easy to use format. The ChimerTrack application, a shareware, user friendly program developed for this purpose, produces a report that automatically summarizes and illustrates the quantitative temporal course of the patient's chimeric status. Such a longitudinal perspective enhances the value of quantitative chimerism monitoring for decisions regarding immunomodulatory post transplant therapy. This information also provides unique insights into the biological dynamics of engraftment underlying the fluctuations in the temporal course of a patient's chimeric status.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) creates a dynamic chimera involving the transplanted donor cells and the recipient-host. For this reason, an accurate assessment of chimerism in the patient's blood or bone marrow provides critical information on the progress of engraftment, and serves as a key element in predicting rejection and relapse. [1] [2] [3] If the evaluation for chimerism is performed qualitatively, the results merely indicate the presence or absence of donor cells in a given sample. In contrast, quantitative methodologies enable estimating the magnitude of chimerism in the patient, based on the ratio between the donor and recipient blood cells, that is, percent chimerism (%Chm). Quantitative chimerism monitoring can be implemented using at least three different approaches. One option entails sampling the patient in response to a specific clinical event, such as change in the patient's medical status or following a therapeutic maneuver. However, the biological implications of such isolated, absolute magnitudes of %Chm are largely unknown, 4 so that these values are most reasonably interpreted semiquantitatively (e.g. low, high). A better utilization of the quantitative data entails testing a patient at fixed intervals post transplantation (e.g. 30 and 100 days), thereby allowing the results to be interpreted in relation to statistical norms for prognosis. [5] [6] [7] [8] [9] This application still does not fully exploit the analytic advantage afforded by a quantitative platform, namely, direct comparisons of numerical results between samples. With the advent of such methodologies, it was possible, for the first time, to track and compare changes in mixed chimerism over time in sequential evaluations. Such longitudinal assessments uniquely reveal the progressive kinetics of each patient's mixed chimeric state. [10] [11] [12] [13] [14] [15] Quantitative chimerism testing, today, commonly relies on an assay for short tandem DNA repeats (STRs). Although, these data can be readily integrated into a longitudinal testing framework, 15, 16 such an approach to chimerism monitoring has not received critical attention in other recent surveys. 2, 17 A review specifically concentrating on STR-based, longitudinal chimerism testing appeared to be a useful and timely undertaking. In the following sections, we scrutinize the technical aspects, interpretive implications and limitations of performing chimerism testing using the STR platform. Based on this background, the advantages and applications of monitoring chimerism longitudinally are considered, including the integration with lineage-specific analysis. Guidelines for laboratory implementation are provided in the final section.
Technical options for quantitative chimerism monitoring
An appropriate laboratory assay for quantitative chimerism testing must differentiate donor (D) from recipient (R) cells in an individual sample. Several methods used for chimerism (Chm) testing are listed in Table 1 , along with their advantages and limitations. As the genome is replete with DNA base sequences that are useful as markers, most of the methods in Table 1 rely on the polymerase chain reaction (PCR), which amplifies these fragments and thereby provides sufficient quantities of fragment DNA for further characterization. As a basis for detection, characterization and/or quantitation, PCR products are often tagged with a fluorescent molecule during amplification. 18 Fluorescence is exploited because of its safety (compared to radioisotopes) and potential for automation, although there are important limitations to this approach, as considered shortly.
An important aspect of any assay's utility is its sensitivity. In the context of chimerism testing, a method's sensitivity refers to the percent minor component in a mixed chimerism that is detectable. An application of this definition, to a cellular assay with a 1% sensitivity, would indicate that one cell from the minor chimeric component (e.g. recipient's) can be detected in a sample mixed with 99 cells representing the major component (e.g. donor's). This usage is somewhat different than the typical laboratory concept that expresses the likelihood of an abnormal value. Specificity, here, is the ability to differentiate between DNA markers for the donor (D) and recipient (R), and is satisfactory for the methods listed in Table 1 .
The sequence-specific primer method is a PCR-based approach that was initially used by HLA laboratories to detect chimerism in blood or bone marrow. As this is a non-quantitative assay, limited to HLA mismatched transplants, it has been replaced by more universal methods based on detecting generic sequence polymorphisms. Although several molecular biological assays are available that exploit these DNA polymorphisms for cellular identity purposes, the markers in widespread use today are referred to as STRs (or microsatellites) and variable number tandem repeats (VNTRs). The STR platform is currently the most flexible and universally applicable for routine quantitative chimerism testing, and consequently constitutes the central focus for much of this review. The method has a sensitivity reported generally as 1-5% for non-fractionated blood or marrow samples, 9, 15, [25] [26] [27] although cell fractionation or enrichment procedures can increase the sensitivity more than a 100-fold. 17 Real-time PCR of single-nucleotide DNA polymorphisms is an emerging technology that could potentially offer greater sensitivity for chimerism detection than STRs. 19 However, most studies have failed to show any clear superiority over STR-based analysis. [20] [21] [22] An exception to this trend, for PCR-based assays for chimerism testing, is represented by fluorescence in situ hybridization (FISH). FISH is a whole cell-based assay that utilizes fluorescent gender 9, 23 and/or tumor markers. 23 The method is generally used for sex mismatched transplants, and exhibits a sensitivity of 1-5%.
9,24 FISH analysis becomes progressively more sensitive as the size of the cell sample increases. Even when STR-PCR is available, estimating chimerism with FISH may be helpful for detecting low levels of a minor chimeric component (see below), and for revealing discrepancies with STR-based estimates; the latter may be indicative of non-neoplastic host hematopoiesis.
Description of STR-based chimerism testing
Pioneered for use in forensic criminal identification, 28 STR-DNA markers can be effectively used to distinguish donor from recipient cells in a HSCT patient. 3, 6, [9] [10] [11] [12] [14] [15] [16] [17] [18] 20, [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] Each marker occurs at a characteristic chromosomal location, and represents a short core DNA nucleotide sequence that is repeated in tandem multiple times -hence short tandem repeat. As a core sequence may be repeated at a given allelic locus from 4 to 50 times, STR markers are considered highly polymorphic and thereby useful for human identity applications. Depicted diagrammatically in Figure 1 is an STR allele consisting of a core repeat, four nucleotides long, that is copied 14 times in tandem. It is part of a set of alleles characteristic of the marker, designated as D3S1358 in the forensic Codex system (Figure 1, bottom) . Over a 100 STRs are currently recognized, located on chromosomes throughout the genome, and new ones are continually being discovered and investigated. Access to this information is available through the short tandem repeat DNA internet database (http://www.cstl.nist.gov/div831/strbase/). The cardinal advantage of the STR platform is that it can be utilized in virtually all donor:recipient combinations, regardless of gender, HLA or disease type; the only exceptions are identical twins. VNTRs are similar to STRs (Table 1) but have larger repeat units (10-100 versus 2-7 bp). Owing to the larger size of the repeat, VNTRs are more prone to inequalities during PCR amplification that may affect quantitation, 28 although some laboratories have used them successfully. 7, 8, 36 STRs are also preferred because they are more polymorphic, and commercial STR-PCR multiplex kits can be utilized on an automated platform; this translates into a more rapid and cost effective assay. Additionally, STRs are superior in that they detect mixed chimerism more frequently, are more sensitive, and exhibit a higher incidence of informative markers. 36 An informative marker locus is characterized by an allelic configuration that enables distinguishing donor from recipient alleles in the chimera; it is a critical property in chimerism testing. 15 The commonly used commercial STR-PCR kits (Applied Biosystems, Foster City, CA, USA) are multiplex and contain 9-10 marker loci, which yield 1-7 informative loci for quantitation of mixed chimerism in a given donor:recipient pair. The example in Figure 2 exemplifies an informative locus. The actual number of useful loci in a particular case depends on the genetic frequencies for the markers in a center's patient/donor subpopulations. 37 However, even among highly consanguineous populations, with a high frequency of shared alleles, we have always found at least one informative locus when a 10 marker, multiplex kit was used. Figure 1 Overview of the STR platform that traces the evaluation of a 14-repeat allele in the D3S1358 marker set. Each repeat is tetranucleotide sequence, when using the ABI system. During electrophoresis, each fluorescently tagged allele is detected as a peak of light emission. The area within the peak correlates with the quantity of STR-DNA at that allele. These data are then used to compute %Chm. Today, the separation and detection stages most commonly utilize capillary electrophoresis (Genetic Analyzer, Applied Biosciences, ABI, Foster City, CA, USA), although some laboratories still use slab gels. With ABI's capillary electrophoresis system, a marker allele is represented in the electropherogram as a 'peak' (Figure 1 ), equivalent to a band in the slab gel methods. Each allele is sized (in bp) and its DNA content estimated using a computer algorithm based on two types of raw data measured during electrophoresis: relative fluorescence units, and elapsed time to detection. Hence, the amount of DNA at an allele is not directly measured but only estimated from indirect measurements that correlate with quantity.
How STR analysis is performed
ABI's platform allows for multiplexing, which involves simultaneous amplification of a number of different STR marker sequences in a single tube (or well). This capability offers important advantages for reliably quantitating chimeric status, as we will see. For multiplexing to work effectively, each PCR primer pair must be optimized not only for amplification of its sequence, but also to minimize interference with the other PCR reactions occurring in the same microenvironment. Owing to practical considerations in designing these multiplex kits, many of the marker sets have alleles in the same size range, so that they migrate during electrophoresis at the same rate. Consequently, to differentiate between such alleles requires tagging the various marker sets, during PCR, with fluorescent molecules distinguished by their emission wavelengths (e.g. blue, green, yellow).
As noted in the foregoing discussion, the platform's fluorescent measurements are used to estimate the quantity of DNA at an allele. This DNA estimate serves as the basis to compute the relative proportion of the D and R components in the sample's chimeric mixture. The actual ratio, utilized in most laboratories for computing percent donor chimerism (%Chm), 3, 11, 14, 25, 27, 29, 30, 34 is summarized by the following formula:
To compute recipient chimerism, 'sum of recipient DNA' is in the numerator (hereafter, %Chm will refer to donor chimerism, unless otherwise qualified). When a multiplex system is used, it is possible to independently compute %Chm for each informative locus in the sample. This provides a more accurate mean value, and enables assessing the statistical variability and reliability of the results, concomitantly. 17 Figure 2 illustrates one locus that typifies an acceptable degree of variability in %Chm between an individual locus in a sample and the overall (mean) sample result.
STR-based analysis can be performed using nonfractionated peripheral blood cells (PBCs) and/or bone marrow samples, as well as lineage-specific hematopoietic cell sub-populations from either source. Although the following discussions will apply to all sample types, a special section has been included to deal with the unique aspects of lineage-specific chimerism analysis (LSCA).
Limitations of the STR platform
Although the current STR technology platform has features well suited for criminological investigations, 28 limitations exist in its application to quantitative chimerism testing that can lead to interpretive pitfalls. The purpose of this section is to present a number of the salient problems, emphasizing how these impact on clinical interpretation.
The most critical limitation of the methodology, inherent in its design, is that the quantity of DNA in an allele is only indirectly estimated from measurements of fluorescence during electrophoresis, as noted above. Unfortunately, different fluorophores vary in their light-emitting efficiencies and the level of fluorescence emission of the dye-tags is not standardized. 18, 28 The indirect assessment of DNA is of particular concern because the platform also lacks an internal calibration for the measurements. As a result, DNA measurements for the same absolute quantity of DNA will not be equivalently estimated in all loci, even in a single patient. Additionally, the fluorescent measurements within a single pair of alleles -either D or R -may not be equivalent either, although under optimal performance conditions they would be expected to be equal. 15 In these cases, therefore, the DNA estimates will be variable and may result in errors in the computation of %Chm. Such problems typically occur when the flourescent signal levels in a locus are low, and allelic DNA measurement may differ within the D pair or R pair of alleles by more than 30%, producing a 10% error in %Chm. 15 The implication of the foregoing is that the measurements produced by the platform are intrinsically semiquantitative (i.e. equivalent to low, medium, high) and have little significance as absolute magnitudes.
Other limitations stem from preparation and operational error. Inadequate PCR amplification, with low levels of product, produces low levels of fluorescence during electrophoresis that result in erratic and unreliable measurements for DNA. Such errors in estimating DNA quantity may independently develop because of intrinsic properties of markers included in the commercial multiplex kits.
38 Table 2 illustrates the occasional 5-10% variability in the %Chm values that can be seen among the 10 multiplex markers that we run routinely. Each sample represents a run on a separate day. These data are based on a simulated chimerism model that optimally provides a true reference level of 50%, free of preparation artifacts. 15 In short, a number of different factors, independently, will alter the estimation of %Chm. If these different types of errors are considered in light of the typical platform sensitivity of 1-5%, the magnitude of the problem is clear: the sum of errors can substantially compromise the validity of any single determination. Errors of 10-15% in estimating %Chm can have important implications at the bedside, and lead to a misjudgement of a patient's chimeric status as stable, when it is actually changing, and vice versa. As the chimeric values can only be reliably interpreted in relation to preceding determinations, such errors would misrepresent the magnitude of the relative change and possibly the direction as well.
As noted earlier, the STR platform has low sensitvity as a chimerism assay. This situation is problematic for two reasons. First, we are often tempted to use STRs for detecting minimal residual disease (MRD) of a malignant cell population. MRD assays should have sensitivities in the range of 10
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À6 but this is not attainable for the standard STR-based methodology used on non-fractionated peripheral blood samples. 17 Second, the foregoing discussion on the variability in fluorescence signal strength implies that the sensitivity can vary between loci within the same sample. 15 The implication is that not all 'informative' loci are equally reliable for evaluating low levels of chimerism. In regards to the ABI system, when the sensitivity of the system for an informative locus is expected to be 5%, then the total detected fluorescent signal (at a locus) has to be great enough so that a 5% minor component will be above the detection threshold, which reflects the noise threshold of the fluorescent sensors. If the sensitivity of a locus is actually 10%, a true 92% donor chimerism level would be reported as 100%, and a true donor chimerism level of 8% would be reported as 0%. An additional implication is that even under optimal performance conditions, if the system is sensitive at the 5% level, then a mixed chimerism between 1 and 4% is artifactually invisible. Indeed, the FISH assay has occasionally proven more sensitive than STRs, in sex mismatched cases, because it directly measures the frequency of the minor component marker. To address this problem of sensitivity assessment for STRs, a simple parameter has been described that is a function of the peak height and the software detection threshold; it is also easy to implement for chimerism testing. 39 The central point here is that some assessment of sample sensitivity is essential in any case with a putative chimerism level of 0 or 100%. With appropriate validation, such data can then serve as a reliable basis for the planning of post transplant salvage therapy, or the early tapering of immunosuppressive therapy.
Assessing the reliability of quantitative estimates of %Chm
The implication of all of the considerations in the preceding section is that an assessment of reliability and sensitivity of the data is essential for the proper interpretation of numerical values for %Chm. For the laboratory, such information may also indicate the need for re-running the original DNA sample before issuing a report. Consequently, we include in our monitoring routine an assessment of several quality control (QC) parameters that indicate the performance of the platform on the sample, and the validity of the results. 39 The approach is applicable to both singleplex and multiplex assays, although a singleplex assay limits the range of QC parameters, as will be explained. Some of the results of the QC evaluation can be usefully added to the actual report, enabling the clinician to judge the relevance of the test data to his management plans, or the adviseability of a new sample evaluation.
To assess the validity of an estimate of %Chm for the sample, or even an individual locus, the following parameters have been found to be most useful: mean of individual locus estimates for %Chm on a sample; coefficient of variation (CE) for a sample; locus error (LE) indicating the deviation of a single locus estimate from the sample mean; sensitivity for detecting a minor component in a locus; DNA measurement error (ME) for gauging the platform's global performance for a locus.
The DNA ME is a non-statistical, operational parameter that represents the deviation of DNA measurements from optimal for each locus individually, and is expressed as %ME. (A more formal description, and a mathematical derivation, is available in previous work.
39 ) It is applicable (Table 3) , so in a sense, it is the most universal of available assessment parameters for chimerism testing. When the value of ME is large, then the DNA measurments for that locus are unreliable, as well as the computed %Chm based on them. For example, when the chimerism level is 50%, and the ME is greater than 15%, then the relative LE in %Chm will be at least a 10%. 39 For a singleplex system, this may be an indication to repeat the study. Its main application for multiplex users is in cases with a large variance between loci and a small number of informative loci. For example, in a recent case with three informative loci, %Chm values for the loci were: 47, 44, 33%, giving a coefficient of variation (CV) of 18%. This value is very high, and suggests the need to eliminate the outlyer(s). To identify it, or them, the %ME was computed with the following results: 18, 13, 26%, respectively. As the 33% Chm value showed a ME of 26%, it was eliminated, giving a new mean sample value of 46% Chm, thereby correcting a 13% error in the original estimate. Figure 3 provides a schematic of the assessment procedure utilizing the CV and ME.
Another useful, but less specific, parameter is %LE, which is a quantitative statement of the difference between an individual locus value and the mean sample value for %Chm; a locus with a LE value above 10% should be rejected and the data re-averaged.
As emphasized earlier, assessing the sensitivity of informative loci in a sample is particularly critical when the results appear to indicate graft failure (0% donor chimerism) or complete engraftment (100%). One useful assessment parameter for sensitivity is referred to as the detection level (DL), 39 which compares the magnitude of the major peak in relation to the required sensitivity level for detecting a minor component at a locus.
Prioritizing parameters
As any measure of error, by itself, will occasionally be misinformative, it is reasonable to use several parameters together (Figures 3 and 4) . Platform performance on the sample can then be reasonably and quickly overviewed to assess the reliability of the measurement data, and the resultant estimations of %Chm. The parameters are assessed in a specific order, namely, CV, LE and ME. The initial assessment is the CV, which reflects the sample variance and thereby provides an overview of the variability between locus estimates, and an indication that additional parameters need to be consulted when the value is high (410%). The reason for giving priority to LE, over ME, is because LE relates to data from the entire sample, whereas ME is an independent evaluator of each locus. In a practical vein, LE also is a more intuitive test and easier to implement in Excel.
These considerations lead to two other global conclusions. First, 'eyeball' assessments of a locus' validity can be quite inaccurate, and hence cannot substitute for a systematic QC of the quantitative results. An additional conclusion is that assessment of the reliability is facilitated by the use of a multiplex system, allowing computation of LE as well as ME. In general, multiplexing offers many more evaluative options, and would therefore be recommended for any routine program.
Why longitudinal testing for individual patients is important
Longitudinal testing entails assessing the relative changes in magnitude and direction for a temporal sequence of chimerism estimates. To achieve this goal, a patient's chimeric status is determined for a sequence of samples, and the cumulative record is reported for each new sample. Figure 3 Schema for reliability testing. Diagram shows the decision process for evaluating the reliability of a locus estimate of % donor chimerism. The two parameters that are used in this example are the coefficient of variation, CV, and the DNA ME.
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Graphic displays of these data facilitate visualizing changes in the chimeric record and appreciating their clinical implications. 15, 16 As a longitudinal analysis focuses on relative changes appearing in the chimeric course, the advantages of this intrinsically semiquantitative, STR platform can be fully exploited. These temporal patterns reflect the dynamic aspects of the graft-host relationship that are central to the whole concept of chimerism monitoring. A longitudinal approach is particularly useful for mixed chimerism that most commonly occurs in association with non-myeloablative conditioning. It is worth emphasizing that this analytic approach does not necessarily involve processing additional samples. If a regular schedule of sampling is already being employed, then longitudinal tracking merely improves data handling and reporting.
Some of the advantages to such an analytic routine, particularly in contrast to single, static values are summarized in Table 4 . In essence, a longitudinal record is more informative clinically, is less likely to be confused with platform artifacts, and is individualized to the particular patient. A drop or rise in a particular patient's chimerism levels can be interpreted as a basis for clinical intervention. In the absence of specific tumor markers, sequential analysis of %Chm may offer the only evidence on which sub-clinical relapse of disease can be assessed ( Figure 5) ; [10] [11] [12] [13] [14] [15] the use of reduced intensity conditioning has made engraftment analysis based on recovery of neutrophil numbers anachronistic.
Isolated absolute values of %Chm are not useful because they are not intrinsically interpretable, despite a few rare exceptions. 4 Whether results are 80 or 95%, it can only be interpreted as a high-level mixed chimera; 15-30%, a low-level chimera. Even though patients may exhibit an individualized range of magnitudes for %Chm in which graft functionality is tolerantly maintained, 4 the pathophysiological implications of the particular magnitudes are unknown.
In addition to its diagnostic relevance for the individual patient, routine longitudinal chimerism monitoring concomitantly generates data on groups of patients regarding the temporal dynamics of their chimeric state. These data can provide an important resource for clinical investigations on the progressive kinetics of engraftment in relation to disease or treatment variables.
Present and potential applications for longitudinal chimerism monitoring
In the course of longitudinal monitoring of a mixed chimerism, a historical, quantitative record of the patient's chimeric status is created. An obvious challenge is to discern the most useful modes of analysis of these data, that is, what parameters are potentially most relevant to clinical Sample results and validation: Laboratory worksheet Figure 4 Chimerism and reliability results for a single sample, as they routinely appear in our ChimerTrack laboratory worksheet. 16, 39 Reliability testing utilizes performance parameters for ME, LE and DL/sensitivity, which are defined in the text. The three-dimensional bar graph (right), displaying the parametric values, is automatically generated by the software in the course of computing the sample's chimerism values (see text). The table (left) is the laboratory's summary of the sample in regards the following parameters: mean %Chm, s.d., CV, ME, LE and DL. The individual locus values for the relevant parameters appear in the top half of the table. Only the mean %Chm, CV and DL are reported to the clinicians.
Table 4
Comparison of approaches to quantitative chimerism monitoring
Longitudinal results
Isolated results At this stage, evaluating the magnitude of change over time is routinely applicable, and particularly useful with mixed chimerism. Two examples of the application of the longitudinal data to clinical care are seen in Figure 5 . The relevance of this parameter to predicting engraftment, rejection and relapse has already been clearly recognized. 9, 10, [12] [13] [14] However, the other two analytic options should be briefly discussed because they may foreshadow new clinical applications of the longitudinal monitoring approach. Our preliminary efforts in developing these applications are illustrated in several actual cases (Figures 6  and 7 ).
Permit interpreting %Chm in
Rate of change over time
It is clear that many patients evince a personal rate at which they achieve their engraftment milestones. For instance, in one recent study evaluating non-myeloablative conditioning, 6 graft rejection in the sample occurred over a period between 23 and 560 days. Although most HSCT patients achieve full engraftment early, a significant minority exhibits a slower progression. From these, and similar observations, the question naturally arises as to whether the rate of change in a mixed chimera overall, or for specific cell types, has any predictive value regarding outcome and/ or the need for early intervention. Such a possibility is not a new idea in the literature, 1 and even on theoretical grounds would be expected, as the kinetics of many biological phenomena are rate dependent.
Two recent cases of reduced intensity conditioning with mixed chimerism reinforce the impression that the rate of change may be a relevant clinical parameter, warranting a further, systematic investigation. Figure 6 graphically depicts the data from two of our HSCT patients with beta-thalassemia major, treated with identical preparatory Longitudinal chimerism testing D Kristt et al regimens. As they were sampled at similar time points, and within the same post transplantation interval, the difference in the rate of improvement in %Chm is clearly seen. In patient A, the patient's chimerism level steadily progressed at an initial rate of 6% per week, over the interval, and engraftment was successful. In contrast, patient B showed a slower rate of improvement (3% per week) in the level of chimerism which was associated with early graft failure. Although these limited examples only have heuristic value, they nonetheless suggest that analysis of rate is an issue deserving critical scrutiny. Moreover, our longitudinal records regularly show variable rates of change in %Chm, both within a given patient's course ( Figure 5 ), and across patients (Figure 6 ), so it would be surprising if rate of change was not found to be a useful aspect of longitudinal quantitative chimerism testing. Indeed, a number of fixedtime-point studies, considered below, would seem to support this view. 9, 42, 48 Extrapolation Historical trends, in a longitudinal data set, can be extrapolated forward in time using techniques already familiar to us from industry and finance. In these settings, statistical models for curve smoothing are routinely exploited for forecasting. The approach is particularly useful for defining trends in data that fluctuate over time, where visual inspection is notoriously imprecise, in contrast to the simple linear trends shown in Figure 6 . Another HSCT case, with a more complex chimerism course Figure 6 Differences in the rate of change in chimeric status. Actual graphs from the report for two HSCT patients with beta-thalassemia major. In patient A, the %Chm improved at a rate of 6%/week, and the engraftment was successful. In patient B, %Chm only increased at a rate of 3%/week, and his graft failed. ing. Sample extrapolation (forecast) based on actual data in a single HSCT patient. The patient's chimerism result data were divided into two groups: the analyzed data set (left box) and the actual outcome data set (right box). Both data sets were analyzed statistically using the power function, which performs curve smoothing, and enables extrapolating the previous data forward. In the box on the right, the forecast curve generated by the power function is in good agreement with the results shown by the data set for actual outcome.
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Longitudinal chimerism testing D Kristt et al (Figure 7 ), illustrates our approach to this type of forecasting. For the sake of analysis, the historical values of an actual patient are divided into two phases: analyzed data set (left) and actual outcome data set (right). This affords us an opportunity to compare the predicted performance with the actual performance in the same patient. The results of the statistical analysis nicely predict the actual, observed outcome. Consequently, even at this stage, extrapolation/forecasting may be useful in alerting clinicians to a case where more careful monitoring would be prudent.
Integrating LSCA with longitudinal testing
LSCA is the assay of choice, particularly for non-ablative HSCTs, according to a 2001 workshop convened to set chimerism testing standards. 40 This approach focuses on an evaluation of specific cell types. They provide information often critical for accurately assessing a patient's prognosis, and characterizing the events of his clinical course. Additionally, the sensitivity of the STR-based assay is increased several orders of magnitude compared to PBCs, as you are dealing with highly enriched subset fractions. 17, 41 This approach is also beneficial in some cases of mixed chimerism, where the myeloid chimerism initially may be dominant and thereby mask clinically significant changes in other subsets. 42 Examples of this masking phenomenon are illustrated in Figure 8 for T-cell chimerism, and in Figure 9 for NK-cell chimerism.
T cells are the most commonly used subset for chimerism determination. Many centers have found that analysis of this cell lineage is particularly useful in regards to early detection of relapse, prediction of graft-versus-host disease (GVHD) risk, and for following the response to therapy (Figure 8 ). 6, 13, 17, 29, 41, [43] [44] [45] [46] [47] [48] Long-term studies on NK cells in HSCTs have indicated that chimeric fluctuations in this lineage are also likely to be valuable prognostically. 6, 49 In stable mixed chimerism, occurring in some non-myeloablative HSCTs, an assessment of the NK-cell chimeric status may be uniquely informative. 50 This subset apparently reflects an independent aspect of the dynamic graft-host relationship, based on the observation that NK-cell mixed chimerism may not correlate with chimeric status in other lineages. 50 Our experience is comparable, as illustrated in Figure 9 .
The general conclusion from these previous studies is that changes in chimerism levels, of individual cell lineages, can serve as harbingers of major post transplantation events that are not apparent from PBC analysis alone. But there is an additional interpretative dimension for these lineage-specific chimerism results; the temporal interplay of chimeric changes between the different lineages also has clinical significance. This integrated perspective of chimeric status provided by multi-lineage analysis is consequently emerging as a useful approach in determining prognosis and managing engraftment and its complications. 6, 13, 17, 46 For instance, one center has reported that in nonmyeloablative HSCTs, a low donor T-cell and NK-cell chimerism on day 14 increases the risk of graft rejection. In contrast, high T-cell chimerism on day 28 indicated an increased probability of GVHD, but earlier occurrences of NK-cell chimerism increased the likelihood of progressionfree survival. 6 Achievement of complete myeloid chimerism also has a relation to T-cell events, although the details are still mooted. 6, 44 Dynamic aspects of NK-cell chimerism, in relationship to simultaneous changes occurring in other subsets, may be particularly informative for assessing putative NK-cell-mediated effects following HSCT. 49 Naturally, not all features of lineage-specific chimeric behavior are so dynamically interactive. Some aspects appear to occur analogously among all cell types, albeit with slight shifts in the time frame, such as the inverse correlation between the rate of achieving complete donor chimerism and relapse. 9, 42, 48 A longitudinal approach is complementary to lineagespecific testing for the same reasons it is useful for the evaluation of PBC-based chimerism. Monitoring chimerism longitudinally is applicable whether the evaluation is on a single subset or multiple lineages, concomitantly. In the case of multi-lineage analysis, the complex temporal, directional and magnitude changes in chimeric level can be clearly visualized, thus aiding clinical interpretation of the findings. From a mechanistic perspective, clarifying the interwoven kinetics of different types of effector lymphocytes is also more informative than an assessment of a static data set. The case shown in Figure 8 illustrates these points and highlights the value of a graphic format for routine chimerism analysis based on lineage-specific sub-populations. In this patient, treated with HSCT for aplastic anemia, LSCA for T cells (CD3 þ ), granulocytes (CD66 þ ), NK cells (CD56 þ ) was performed periodically in conjunction with the continual assessment of PBC chimerism. This routine evaluative approach captured three important facets of the case: (1) a dramatic response to immunomodulatory therapy (discontinuation of cyclosporin), (2) the mechanistic cellular dynamics underlying the patient's chimeric status, (3) the masking effect resulting from high levels of granulocytic engraftment (reflected in donor myeloid chimerism of 90%) obscuring the occurrence of poor T-cell engraftment manifested in 7% Chm that required therapeutic intervention. After cyclosporin was discontinued, a substantial, progressive improvement in T-cell chimerism occurred over the ensuing weeks. The electropherograms for all fractions derived from the last sample are shown in the inset. Their corresponding peak measurements yielded a 34% T-cell donor chimerism accompanied by an 80-85% Chm for the other cell lines.
Despite the advantages of integrating LSCA into a longitudinal testing program, some practical constraints exist. The increased cost, labor and technical problems, such as low level of DNA in some fractions, need to be considered. Nonetheless, despite some drawbacks, integrating LSCA into a longitudinal framework enhances the clinical value of the data for early detection of relapse, graft failure or response to therapy. Longitudinal multi-lineage evaluations also provide unique mechanistic insights into the engraftment process and, and hence, the dynamics of the graft-host relationship.
Routine implementation of longitudinal chimerism testing
Although the value of longitudinal monitoring is amply documented, [9] [10] [11] 14 it may not be practiced routinely because of a perceived burden on the laboratory. As a framework to undertake such a program, a multiplex approach may be most practicable because of the commercial availability of STR-PCR test kits for forensic human identification purposes. The kits facilitate overcoming the technical challenge, and multiplexing enables proper assessment of the platform's performance and the results' reliability, as discussed above.
Although many laboratories engaged in monitoring still perform the computations manually (personal observations), a manual approach essentially precludes longitudinal testing and reliability assessment of the data; it becomes too labor intense. The need for reliability testing, as explained above, is not a mere convenience, but plays a critical role, particularly in substantiating a report value of 0 or 100%, that is, graft failure and complete engraftment. In the current age of off-the-shelf high quality software, a spreadsheet program, such as Excel, will be found essential to implement such a program. Laboratories that already have integrated Excel for record keeping and computation will find that its utilization can be readily extended to facilitate the longitudinal reporting of chimerism results. In these cases, the previous sample results are probably already being stored in an Excel file. Using these data, an Excel worksheet can be utilized to simultaneously compute %Chm and reliability parameters based on the same imported data. This strategy obviates the need for a separate QC procedure. 51 Our version of this idea, called ChimerTrack, 52 has an embedded report template -page 1 of the worksheet -that facilitates reporting the results on a current sample, as well as an updateable graphic display of the longitudinal history of the patient ( Figures 5, 6 and 8) . The parametric reliability assessment can be easily integrated into the worksheet format (Figure 4 ). Reporting longitudinal results need not be time consuming, either. Once the raw electrophoretic data (Figures 2, 8 and 9 ) have been imported into the worksheet, a complete report can be generated within 10-15 min, regardless of the complexity of the chimeric course. We continue to share versions of the program with co-workers interested in implementing a longitudinal testing approach. It can be obtained by writing to the authors.
As noted earlier, LSCA 12, 13, 17, 41 improves the sensitivity, specificity and mechanistic implications of the chimerism test results. Data on the different cell lines can be analyzed and compared using the same software framework described above (Figure 8 ), so that a time-based (longitudinal) assessment of the interactions between the various lineages is available for each sample. Our personal experience shows the use of immuno-magnetic beads for LSCA is convenient and effective, with cell line purity 498%. The practical limitations of LSCA, in terms of routine chimerism testing, were discussed earlier.
Another consideration in undertaking such a program is the source of the samples. An earlier report 40 concluded that PBCs are more useful for chimerism analysis than bone marrow samples. Other workers have found a parallelism in chimeric course of both sample populations. 42 Our own experience has shown an unpredictable relationship between the results from both sources. When there is a difference between PBC-based values and marrow-derived results, the latter is usually lower, as previously noted. 42 Further studies are warranted to better characterize the pathophysiological relationships between these two cell reservoirs, and the impact of preferential testing on prognosis.
One final practical issue: how frequently should one sample the patient for optimum information during longitudinal tracking? In addressing this question, our premise is that that one simple schedule will not be appropriate for all cases. Indeed, it is this very uniqueness of each patient's chimeric status that justifies longitudinal testing. Nonetheless, guidelines are useful to provide a general framework. For instance, in non-ablative HSCT, one group recommended performing chimerism testing at 1, 3, 6 and 12 months. 40 A more recent report recommended a weekly analysis for the initial 200 days following HSCT for malignant disease. 46 Our general practice is to monitor more closely during the early post-HSCT course. The levels and rates of change in two or three samples in the first month typically indicate whether the patient is likely to be a complete (100% donor) or mixed chimera, or whether the graft is likely to fail. In the latter situation, closer follow-up may be indicated. Once a stable pattern is achieved, sampling becomes less frequent beginning with 1 test per month, tapering to 1 test per 3-6 months, depending on the stability of the response. Our long-term follow-ups are performed once a year.
Summing-up
The current status of longitudinal quantitative chimerism testing, following HSCT, has been reviewed in terms of its clinical importance, limitations and routine technical feasibility. As a monitoring approach, it optimally exploits the potential of the STR platform, namely, the ability to compare numerical results between samples. This is particularly useful in patients undergoing reduced intensity conditioning, where mixed chimerism is common. A longitudinal approach can be readily integrated with LSCA, thereby augmenting the sensitivity, specificity and mechanistic implications of the data. At a global level, the longitudinal perspective is important because it highlights the kinetics of chimeric patterns in time that are crafted by the dynamic relation between the host and graft.
Endnote
The parameters discussed in the section Assessing the reliability of quantitative estimates of %Chm were developed for the ABI Genescan program as the data source. The new version of this software, GeneMapper, has several other QC parameters available but these are not focused on chimerism monitoring needs, and require a sophisticated understanding of the software. Consequently, the GeneMapper QC utilities are not recommended, but they would be superior to running STRs without any QC monitoring program.
